Kevin P Labadie1, Donald K Hamlin2, Aimee Kenoyer3, Sara K Daniel1, Alan F Utria1, Andrew D Ludwig1, Heidi L Kenerson1, Lily Li4, Jonathan G Sham1, Delphine L Chen5, Johnnie J Orozco3, Raymond S Yeung1, Chris Orvig6, Yawen Li2, D Scott Wilbur2, James O Park7. 1. Department of Surgery, University of Washington, Seattle, Washington. 2. Department of Radiation Oncology, University of Washington, Seattle, Washington. 3. Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington. 4. Life Sciences Division, TRIUMF, and Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada. 5. Department of Radiology, University of Washington, Seattle, Washington. 6. Medicinal Inorganic Chemistry Group, Department of Chemistry, University of British Columbia, Vancouver, British Columbia, Canada. 7. Department of Surgery, University of Washington, Seattle, Washington; jopark@uw.edu.
Abstract
Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide, with limited therapeutic options for advanced disease. Targeted α-therapy is an emerging class of targeted cancer therapy in which α-particle-emitting radionuclides, such as 227Th, are delivered specifically to cancer tissue. Glypican-3 (GPC3) is a cell surface glycoprotein highly expressed on HCC. In this study, we describe the development and in vivo efficacy of a 227Th-labeled GPC3-targeting antibody conjugate (227Th-octapa-αGPC3) for treatment of HCC in an orthotopic murine model. Methods: The chelator p-SCN-Bn-H4octapa-NCS (octapa) was conjugated to a GPC3-targeting antibody (αGPC3) for subsequent 227Th radiolabeling (octapa-αGPC3). Conditions were varied to optimize radiolabeling of 227Th. In vitro stability was evaluated by measuring the percentage of protein-bound 227Th by γ-ray spectroscopy. An orthotopic athymic Nu/J murine model using HepG2-Red-FLuc cells was developed. Biodistribution and blood clearance of 227Th-octapa-αGPC3 were evaluated in tumor-bearing mice. The efficacy of 227Th-octapa-αGPC3 was assessed in tumor-bearing animals with serial measurement of serum α-fetoprotein at 23 d after injection. Results: Octapa-conjugated αGPC3 provided up to 70% 227Th labeling yield in 2 h at room temperature. In the presence of ascorbate, at least 97.8% of 227Th was bound to αGPC3-octapa after 14 d in phosphate-buffered saline. In HepG2-Red-FLuc tumor-bearing mice, highly specific GPC3 targeting was observed, with significant 227Th-octapa-αGPC3 accumulation in the tumor over time and minimal accumulation in normal tissue. Twenty-three days after treatment, a significant reduction in tumor burden was observed in mice receiving a 500 kBq/kg dose of 227Th-octapa-αGPC3 by tail-vein injection. No acute off-target toxicity was observed, and no animals died before termination of the study. Conclusion: 227Th-octapa-αGPC3 was observed to be stable in vitro; maintain high specificity for GPC3, with favorable biodistribution in vivo; and result in significant antitumor activity without significant acute off-target toxicity in an orthotopic murine model of HCC.
Hepatocellular carcinoma (HCC) is a significant cause of morbidity and mortality worldwide, with limited therapeutic options for advanced disease. Targeted α-therapy is an emerging class of targeted cancer therapy in which α-particle-emitting radionuclides, such as 227Th, are delivered specifically to cancer tissue. Glypican-3 (GPC3) is a cell surface glycoprotein highly expressed on HCC. In this study, we describe the development and in vivo efficacy of a 227Th-labeled GPC3-targeting antibody conjugate (227Th-octapa-αGPC3) for treatment of HCC in an orthotopic murine model. Methods: The chelator p-SCN-Bn-H4octapa-NCS (octapa) was conjugated to a GPC3-targeting antibody (αGPC3) for subsequent 227Th radiolabeling (octapa-αGPC3). Conditions were varied to optimize radiolabeling of 227Th. In vitro stability was evaluated by measuring the percentage of protein-bound 227Th by γ-ray spectroscopy. An orthotopic athymic Nu/J murine model using HepG2-Red-FLuc cells was developed. Biodistribution and blood clearance of 227Th-octapa-αGPC3 were evaluated in tumor-bearing mice. The efficacy of 227Th-octapa-αGPC3 was assessed in tumor-bearing animals with serial measurement of serum α-fetoprotein at 23 d after injection. Results: Octapa-conjugated αGPC3 provided up to 70% 227Th labeling yield in 2 h at room temperature. In the presence of ascorbate, at least 97.8% of 227Th was bound to αGPC3-octapa after 14 d in phosphate-buffered saline. In HepG2-Red-FLuc tumor-bearing mice, highly specific GPC3 targeting was observed, with significant 227Th-octapa-αGPC3 accumulation in the tumor over time and minimal accumulation in normal tissue. Twenty-three days after treatment, a significant reduction in tumor burden was observed in mice receiving a 500 kBq/kg dose of 227Th-octapa-αGPC3 by tail-vein injection. No acute off-target toxicity was observed, and no animals died before termination of the study. Conclusion: 227Th-octapa-αGPC3 was observed to be stable in vitro; maintain high specificity for GPC3, with favorable biodistribution in vivo; and result in significant antitumor activity without significant acute off-target toxicity in an orthotopic murine model of HCC.
Authors: John M Pagel; Dana C Matthews; Aimee Kenoyer; Donald K Hamlin; Daniel S Wilbur; Darrell R Fisher; Ajay K Gopal; Yukang Lin; Laura Saganic; Frederick R Appelbaum; Oliver W Press Journal: Cancer Res Date: 2009-01-01 Impact factor: 12.701
Authors: Nathalie Percie du Sert; Viki Hurst; Amrita Ahluwalia; Sabina Alam; Marc T Avey; Monya Baker; William J Browne; Alejandra Clark; Innes C Cuthill; Ulrich Dirnagl; Michael Emerson; Paul Garner; Stephen T Holgate; David W Howells; Natasha A Karp; Stanley E Lazic; Katie Lidster; Catriona J MacCallum; Malcolm Macleod; Esther J Pearl; Ole H Petersen; Frances Rawle; Penny Reynolds; Kieron Rooney; Emily S Sena; Shai D Silberberg; Thomas Steckler; Hanno Würbel Journal: Exp Physiol Date: 2020-07-14 Impact factor: 2.969
Authors: Richard S Finn; Shukui Qin; Masafumi Ikeda; Peter R Galle; Michel Ducreux; Tae-You Kim; Masatoshi Kudo; Valeriy Breder; Philippe Merle; Ahmed O Kaseb; Daneng Li; Wendy Verret; Derek-Zhen Xu; Sairy Hernandez; Juan Liu; Chen Huang; Sohail Mulla; Yulei Wang; Ho Yeong Lim; Andrew X Zhu; Ann-Lii Cheng Journal: N Engl J Med Date: 2020-05-14 Impact factor: 91.245
Authors: Shyril O'Steen; Melissa L Comstock; Johnnie J Orozco; Donald K Hamlin; D Scott Wilbur; Jon C Jones; Aimee Kenoyer; Margaret E Nartea; Yukang Lin; Brian W Miller; Theodore A Gooley; Sherilyn A Tuazon; Brian G Till; Ajay K Gopal; Brenda M Sandmaier; Oliver W Press; Damian J Green Journal: Blood Date: 2019-10-10 Impact factor: 22.113
Authors: Jonathan G Sham; Forrest M Kievit; John R Grierson; Peter A Chiarelli; Robert S Miyaoka; Miqin Zhang; Raymond S Yeung; Satoshi Minoshima; James O Park Journal: J Nucl Med Date: 2014-10-30 Impact factor: 10.057
Authors: Donghee Kim; Andrew A Li; Brandon J Perumpail; Chiranjeevi Gadiparthi; Won Kim; George Cholankeril; Jeffrey S Glenn; Stephen A Harrison; Zobair M Younossi; Aijaz Ahmed Journal: Hepatology Date: 2019-02-11 Impact factor: 17.425
Authors: Kirsten L Moek; Rudolf S N Fehrmann; Bert van der Vegt; Elisabeth G E de Vries; Derk J A de Groot Journal: Am J Pathol Date: 2018-06-21 Impact factor: 4.307
Authors: Andrew D Ludwig; Kevin P Labadie; Y David Seo; Donald K Hamlin; Holly M Nguyen; Vimukta M Mahadev; Raymond S Yeung; D S Wilbur; James O Park Journal: J Oncol Date: 2019-09-15 Impact factor: 4.375